Managing Wyburn-Mason Disease with a Thalamic Arteriovenous Malformation
Author Information
Author(s): Dhatt Jovan, Houser Karis, Szymanski Kathryn A, Halderman Kelly, Kuwabara Michael
Primary Institution: Midwestern University – Arizona College of Osteopathic Medicine
Hypothesis
Can trametinib effectively manage high-grade arteriovenous malformations in Wyburn-Mason disease?
Conclusion
The use of trametinib in treating high-grade AVMs in Wyburn-Mason disease can lead to complications, necessitating careful monitoring.
Supporting Evidence
- Wyburn-Mason disease is characterized by complex arteriovenous malformations affecting the brain.
- Trametinib is a MEK inhibitor that has shown potential in managing AVM progression.
- The patient experienced significant complications after nine months of trametinib treatment.
- Careful monitoring is essential when using MEK inhibitors for high-grade AVMs.
Takeaway
This study is about a 19-year-old girl with a rare brain condition who was treated with a medication that helped at first but later caused problems, showing that treatment needs to be very carefully managed.
Methodology
The patient was treated with trametinib and monitored through MRI and clinical assessments.
Limitations
The study is based on a single case, limiting the generalizability of the findings.
Participant Demographics
19-year-old female
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website